Cargando…

Prognostic Value and Quantitative CT Analysis in RANKL Expression of Spinal GCTB in the Denosumab Era: A Machine Learning Approach

SIMPLE SUMMARY: Prognostic assessment of giant cell tumor of bone (GCTB) is an ongoing challenge in the treatment and management of bone tumors. Recurrence rates of spinal GCTB are higher compared to GCTB in other bone sites, presumably due to a more aggressive pathology and/or the conservative surg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qizheng, Chen, Yongye, Qin, Siyuan, Liu, Xiaoming, Liu, Ke, Xin, Peijin, Zhao, Weili, Yuan, Huishu, Lang, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658803/ https://www.ncbi.nlm.nih.gov/pubmed/36358621 http://dx.doi.org/10.3390/cancers14215201

Ejemplares similares

MRI feature-based radiomics models to predict treatment outcome after stereotactic body radiotherapy for spinal metastases
por: Chen, Yongye, et al.
Publicado: (2023)

Prediction of Primary Tumor Sites in Spinal Metastases Using a ResNet-50 Convolutional Neural Network Based on MRI
por: Liu, Ke, et al.
Publicado: (2023)

Differentiation of predominantly osteolytic from osteoblastic spinal metastases based on standard magnetic resonance imaging sequences: a comparison of radiomics model versus semantic features logistic regression model findings
por: Liu, Ke, et al.
Publicado: (2022)

A Multiparametric Method Based on Clinical and CT-Based Radiomics to Predict the Expression of p53 and VEGF in Patients With Spinal Giant Cell Tumor of Bone
por: Wang, Qizheng, et al.
Publicado: (2022)

Feasibility of AI-assisted compressed sensing protocols in knee MR imaging: a prospective multi-reader study
por: Wang, Qizheng, et al.
Publicado: (2023)

Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study
por: Palmerini, Emanuela, et al.
Publicado: (2022)

Recurrence of GCTB of Wrist in an Autografted Non-vascularized Fibula: A Case Report
por: Kamat, Amar, et al.
Publicado: (2022)

Prediction of the early recurrence in spinal giant cell tumor of bone using radiomics of preoperative CT: Long-term outcome of 62 consecutive patients
por: Wang, Qizheng, et al.
Publicado: (2021)

Targeting the tumour microenvironment: denosumab, a new RANKL inhibitor
por: Coleman, RE
Publicado: (2009)

Assessment of axial spondyloarthritis activity using a magnetic resonance imaging-based multi-region-of-interest fusion model
por: Xin, Peijin, et al.
Publicado: (2023)

Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
por: Zhang, Ning, et al.
Publicado: (2020)

Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review
por: Wang, Daoxi, et al.
Publicado: (2023)

Radiologic and clinical changes after denosumab treatment for giant cell tumors of the mobile spine: a quantitative study
por: Yuan, Bei, et al.
Publicado: (2022)

Radiomics from Mesorectal Blood Vessels and Lymph Nodes: A Novel Prognostic Predictor for Rectal Cancer with Neoadjuvant Therapy
por: Qin, Siyuan, et al.
Publicado: (2023)

Primary leiomyosarcoma of the spine: an analysis of imaging manifestations and clinicopathological findings
por: Zhang, Jiahui, et al.
Publicado: (2022)

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
por: Schieferdecker, Aneta, et al.
Publicado: (2014)

Denosumab Attenuates Glucolipotoxicity-Induced β-Cell Dysfunction and Apoptosis by Attenuating RANK/RANKL Signals
por: Lin, Sheng-Chieh, et al.
Publicado: (2023)

Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Multicentric carpotarsal osteolysis syndrome (MCTO) with generalized high bone turnover and high serum RANKL: Response to denosumab
por: Regev, Ravit, et al.
Publicado: (2021)

Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: Effect of denosumab on glycemic parameters
por: Abe, Ichiro, et al.
Publicado: (2019)

A systematic review of radiomics in giant cell tumor of bone (GCTB): the potential of analysis on individual radiomics feature for identifying genuine promising imaging biomarkers
por: Zhong, Jingyu, et al.
Publicado: (2023)

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells
por: Cuyàs, Elisabet, et al.
Publicado: (2017)

Intravoxel incoherent motion to differentiate spinal metastasis: A pilot study
por: Zhang, Enlong, et al.
Publicado: (2022)

Epithelioid hemangioendothelioma of the spine: an analysis of imaging findings
por: Chen, Yongye, et al.
Publicado: (2022)

Denosumab inhibits MCF-7 cell line-induced spontaneous osteoclastogenesis via the RANKL/MALAT1/miR-124 axis
por: Feng, Qi, et al.
Publicado: (2020)

Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials
por: Lu, Junjie, et al.
Publicado: (2023)

Personalized medicine modality based on patient-derived xenografts from a malignant transformed GCTB harboring H3F3A G34W mutation
por: Yafei, Jiang, et al.
Publicado: (2021)

Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis
por: Lleo, Ana, et al.
Publicado: (2016)

MON-LB72 Multicentric Carpotarsal Osteolysis Syndrome (MCTO) Has a Generalized High Turnover Bone Phenotype, High S RANKL and Responds to Denosumab
por: Regev, Ravit, et al.
Publicado: (2020)

RANKL Cytokine: From Pioneer of the Osteoimmunology Era to Cure for a Rare Disease
por: Lo Iacono, Nadia, et al.
Publicado: (2013)

Deep learning-assisted classification of calcaneofibular ligament injuries in the ankle joint
por: Ni, Ming, et al.
Publicado: (2022)

The Efficacy of Denosumab in Treating Spinal Aneurysmal Bone Cyst: A Case Report
por: Kotaka, Shinji, et al.
Publicado: (2023)

Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL
por: Jang, Yuria, et al.
Publicado: (2021)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Denosumab and osteonecrosis of the jaw
por: Bower, Robert
Publicado: (2019)

Osteonecrosis of the jaw and denosumab
por: Goss, Alastair N
Publicado: (2022)

Denosumab and muscle performance
por: Rolvien, Tim, et al.
Publicado: (2022)

Implications of enolase in the RANKL-mediated osteoclast activity following spinal cord injury
por: SHAMS, Ramsha, et al.
Publicado: (2021)

A bibliometric research based on hotspots and frontier trends of denosumab
por: Ren, Bolin, et al.
Publicado: (2022)

The Decalcification of Cervicothoracic Spinal Metastasis of Breast Cancer Due to Discontinuation of Denosumab: A Case Report
por: Tatsumura, Masaki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8f09t55ld6442b1ahqu0072edg